<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01957085</url>
  </required_header>
  <id_info>
    <org_study_id>Undiagnosed Hepatitis C</org_study_id>
    <nct_id>NCT01957085</nct_id>
  </id_info>
  <brief_title>Undiagnosed Hepatitis C Infection in an Urban Hospital</brief_title>
  <official_title>Incidence of Undiagnosed Hepatitis C Infection in an Urban Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Services, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Temple University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Centers for Disease Control and Prevention estimates that there are approximately 3.2
      million people in the United States infected with hepatitis C and a significant percentage of
      these patients are unaware of their diagnosis. This study will attempt to determine the point
      prevalence of undiagnosed hepatitis C infection in an urban hospital population. All patients
      admitted to the hospital on two separate days will have hepatitis C testing done on leftover
      serum and plasma that was collected as part of routine inpatient lab work. Our primary goal
      is to determine the number of undiagnosed hepatitis C infected patients in our hospitalized
      population. We will also compare these rates to specific demographic characteristics, such as
      age, race, gender, zip code and type of insurance to see if any associations exist between
      these demographics and undiagnosed hepatitis C infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      De-identified study of Hepatitis C infection point prevalence in the inpatient setting of an
      inner city hospital.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Point Prevalence of Hepatitis C Infection</measure>
    <time_frame>Single 24 hour period</time_frame>
    <description>The point prevalence of hepatitis C infection in our hospitalized patients will be measured on a single day. All leftover plasma/serum samples will be de-identified and tested for hepatitis C antibody and if antibody positive will be tested for hepatitis C polymerase chain reaction. Results reported as percentage of subjects who are viremic.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Number of Evaluable Participants Age 50 or Older and Point Prevalence of Hepatitis C Viremia</measure>
    <time_frame>Single 24 hour period</time_frame>
    <description>Association between point prevalence of hepatitis C viremia and evaluable participants age 50 or older.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Evaluable Patients With Hepatitis C Viremia by Gender</measure>
    <time_frame>Single 24 hour period</time_frame>
    <description>Association between the incidence of hepatitis C infection and gender.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients With Hepatitis C Viremia by Race and Ethnicity</measure>
    <time_frame>Single 24 hour period</time_frame>
    <description>Association between the incidence of hepatitis C infection by race and ethnicity</description>
  </other_outcome>
  <other_outcome>
    <measure>Association Between Evaluable Viremic Patients and Length of Stay in the Hospital</measure>
    <time_frame>Single 24 hour period</time_frame>
    <description>Association between hepatitis C infection and the patient's length of stay in the hospital.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Evaluable Patients by Prior Visits to the Health System</measure>
    <time_frame>Single 24 hour period</time_frame>
    <description>Number of evaluable patients with at least one prior health system visit in the past 3 years by hepatitis C viremia</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">366</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Hospitalized Patients</arm_group_label>
    <description>Observation only. All patients admitted to Temple University Hospital on the study day. Observational only, no intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>observation only</intervention_name>
    <description>This is an observational only, nonintervention study. There will be no patient contact. This was a de-identified point prevalence study of hepatitis C infection in hospitalized patients in an inner city hospital.</description>
    <arm_group_label>Hospitalized Patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      All leftover sera and plasma will be banked at -70 degrees Celsius in a secure laboratory for
      potential future research activities
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients admitted to Temple University Hospital on the study dates
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient admitted to Temple University Hospital on either of the study dates

        Exclusion Criteria:

          -  Patients admitted on both study dates will only be counted once
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Bettiker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012 Feb 21;156(4):271-8. doi: 10.7326/0003-4819-156-4-201202210-00004. Erratum in: Ann Intern Med. 2012 Jun 5;156(11):840.</citation>
    <PMID>22351712</PMID>
  </reference>
  <reference>
    <citation>Brady KA, Weiner M, Turner BJ. Undiagnosed hepatitis C on the general medicine and trauma services of two urban hospitals. J Infect. 2009 Jul;59(1):62-9. doi: 10.1016/j.jinf.2009.04.008. Epub 2009 May 3.</citation>
    <PMID>19473706</PMID>
  </reference>
  <reference>
    <citation>Seamon MJ, Ginwalla R, Kulp H, Patel J, Pathak AS, Santora TA, Gaughan JP, Goldberg AJ, Tedaldi EM. HIV and hepatitis in an urban penetrating trauma population: unrecognized and untreated. J Trauma. 2011 Aug;71(2):306-10; discussion 311. doi: 10.1097/TA.0b013e31822178bd.</citation>
    <PMID>21825931</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 24, 2013</study_first_submitted>
  <study_first_submitted_qc>October 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <results_first_submitted>April 6, 2016</results_first_submitted>
  <results_first_submitted_qc>April 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 24, 2020</results_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This is a de-identified, observational only study with no intervention. Individual participant data will not be released.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hospitalized Patients</title>
          <description>All patients admitted to Temple University Hospital on the study day
Observation only, no intervention: Hepatitis C antibody and RNA measured from leftover sera and plasma from the clinical laboratory</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="366">Per Institutional Review Board requirements, exact dates are not to be reported</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="366">Per Institutional Review Board, exact dates are not to be reported</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hospitalized Patients</title>
          <description>All patients admitted to Temple University Hospital on the study day
Observation only, no intervention: HCV ab and RNA measured from leftover sera and plasma from the clinical laboratory</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="366"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="238"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Participants may have selected more than one category for race/ethnicity, and thus the total in the race category is more than the total participants.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latino/a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Country of residence was not determined. Zip code of residence was taken from hospital records</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>h/o: HIV, Hepatitis C infection, Intravenous drug use, HCV treatment</title>
          <description>This category only counts participants with a particular characteristic. Thus, the total number will be less than the total participants.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>h/o Human Immunodeficiency Virus Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>h/o Hepatitis C Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>h/o intravenous drug use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>h/o Hepatitis C treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Point Prevalence of Hepatitis C Infection</title>
        <description>The point prevalence of hepatitis C infection in our hospitalized patients will be measured on a single day. All leftover plasma/serum samples will be de-identified and tested for hepatitis C antibody and if antibody positive will be tested for hepatitis C polymerase chain reaction. Results reported as percentage of subjects who are viremic.</description>
        <time_frame>Single 24 hour period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hospitalized Patients</title>
            <description>All patients admitted to Temple University Hospital on the study day
Observation only, no intervention: HCV ab and RNA measured from leftover sera and plasma from the clinical laboratory</description>
          </group>
        </group_list>
        <measure>
          <title>Point Prevalence of Hepatitis C Infection</title>
          <description>The point prevalence of hepatitis C infection in our hospitalized patients will be measured on a single day. All leftover plasma/serum samples will be de-identified and tested for hepatitis C antibody and if antibody positive will be tested for hepatitis C polymerase chain reaction. Results reported as percentage of subjects who are viremic.</description>
          <units>percentage of total subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Evaluable Participants Age 50 or Older and Point Prevalence of Hepatitis C Viremia</title>
        <description>Association between point prevalence of hepatitis C viremia and evaluable participants age 50 or older.</description>
        <time_frame>Single 24 hour period</time_frame>
        <population>Number of patients with evaluable plasma</population>
        <group_list>
          <group group_id="O1">
            <title>Hospitalized Patients/Participants</title>
            <description>All patients admitted to Temple University Hospital on the study day
Observation only, no intervention: HCV ab and RNA measured from leftover sera and plasma from the clinical laboratory</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Evaluable Participants Age 50 or Older and Point Prevalence of Hepatitis C Viremia</title>
          <description>Association between point prevalence of hepatitis C viremia and evaluable participants age 50 or older.</description>
          <population>Number of patients with evaluable plasma</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title># viremic &gt;=50 yrs w h/o HCV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># viremic &gt;=50 yrs w/o h/o HCV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without viremia &gt;=50 yrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>=.04</p_value>
            <p_value_desc>Statistical significance was set at .05 to determine statistical significance.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Evaluable Patients With Hepatitis C Viremia by Gender</title>
        <description>Association between the incidence of hepatitis C infection and gender.</description>
        <time_frame>Single 24 hour period</time_frame>
        <population>Number of evaluable patients</population>
        <group_list>
          <group group_id="O1">
            <title>Hospitalized Patients/Participants</title>
            <description>All patients admitted to Temple University Hospital on the study day
Observation only, no intervention: HCV ab and RNA measured from leftover sera and plasma from the clinical laboratory</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Evaluable Patients With Hepatitis C Viremia by Gender</title>
          <description>Association between the incidence of hepatitis C infection and gender.</description>
          <population>Number of evaluable patients</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="341"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Viremic females with history of Hepatitis C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viremic females without a history of Hepatitis C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Females without viremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viremic males with history of Hepatitis C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viremic males without history of Hepatitis C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Males without viremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&gt;.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Hepatitis C Viremia by Race and Ethnicity</title>
        <description>Association between the incidence of hepatitis C infection by race and ethnicity</description>
        <time_frame>Single 24 hour period</time_frame>
        <population>Number of evaluable patients</population>
        <group_list>
          <group group_id="O1">
            <title>Hospitalized Patients/Participants</title>
            <description>All patients admitted to Temple University Hospital on the study day
Observation only, no intervention: HCV ab and RNA measured from leftover sera and plasma from the clinical laboratory</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Hepatitis C Viremia by Race and Ethnicity</title>
          <description>Association between the incidence of hepatitis C infection by race and ethnicity</description>
          <population>Number of evaluable patients</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="341"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Viremic AA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viremic White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viremic Latino/a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viremic Other/unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-viremic AA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-viremic white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-viremic Latino/a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-viremic other/unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&gt;.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Association Between Evaluable Viremic Patients and Length of Stay in the Hospital</title>
        <description>Association between hepatitis C infection and the patient's length of stay in the hospital.</description>
        <time_frame>Single 24 hour period</time_frame>
        <population>Length of stay in days</population>
        <group_list>
          <group group_id="O1">
            <title>Hospitalized Patients</title>
            <description>All patients admitted to Temple University Hospital on the study day
Observation only, no intervention: HCV ab and RNA measured from leftover sera and plasma from the clinical laboratory</description>
          </group>
        </group_list>
        <measure>
          <title>Association Between Evaluable Viremic Patients and Length of Stay in the Hospital</title>
          <description>Association between hepatitis C infection and the patient's length of stay in the hospital.</description>
          <population>Length of stay in days</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="341"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Length of stay, viremic patients w h/o HCV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="4" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Length of stay, viremic patients w/o h/o HCV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="0" upper_limit="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Length of stay, aviremic patients</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="6" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Evaluable Patients by Prior Visits to the Health System</title>
        <description>Number of evaluable patients with at least one prior health system visit in the past 3 years by hepatitis C viremia</description>
        <time_frame>Single 24 hour period</time_frame>
        <population>Number of evaluable patients</population>
        <group_list>
          <group group_id="O1">
            <title>Hospitalized Patients</title>
            <description>All patients admitted to Temple University Hospital on the study day
Observation only, no intervention: HCV ab and RNA measured from leftover sera and plasma from the clinical laboratory</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Evaluable Patients by Prior Visits to the Health System</title>
          <description>Number of evaluable patients with at least one prior health system visit in the past 3 years by hepatitis C viremia</description>
          <population>Number of evaluable patients</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="341"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Viremic patient, h/o HCV with &gt;= 1 prior visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viremic patient, no h/o HCV with &gt;=1 prior visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Viremic patient, with &gt;=1 prior visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viremic patient, h/o HCV, no prior visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viremic patient, no h/o HCV, no prior visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-viremic patient, no prior visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&gt;.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>This was an observation only, no intervention study. There were no adverse advents due to the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hospitalized Patients</title>
          <description>All patients admitted to Temple University Hospital on the study day
Observation only, no intervention: HCV ab and RNA measured from leftover sera and plasma from the clinical laboratory</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>These results may apply only to inner city, academic medical center hospitals.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert L. Bettiker, MD/MGA, Principle Investigator</name_or_title>
      <organization>Lewis Katz School of Medicine</organization>
      <phone>215.707.1982</phone>
      <email>robert.bettiker@temple.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

